CECOG Academy
Avatar

How to Pick the Individual (Neo)adjuvant Treatment Concept in Resectable PAC

By CECOG Academy FEATURING Eric Van Cutsem
By CECOG Academy FEATURING Eric Van Cutsem
0 views
September 6, 2022
Comments 0
Login to view comments. Click here to Login

Featured Video

20:00
Exelixis

Child-Pugh Classification and its Role in Treatment Decisions in Pat…

Feat. P. Gholam

Featured Video

10:25
Exelixis

Explore the mechanism of Action of a TKI in HCC

Feat. W. Keiser

Recommended

AUTOPLAY
57:44
Vogl, NY

Vogl,NY on How to Ask Good Questions at Medical Meetings

Feat. S. Vogl
27:04
Fengting Yan

Cancer Screening Molecular Tools

17:50
AdventHealth

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Feat. G. Sonpavde
09:01
Integrity CE

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Feat. L. Zheng
12:50
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "The GIANT Trial (EA2186) - Gem & nab-…

Feat. E. Dotan
10:22
Houston Methodist Hospital

mRNA Vaccine in Treatment of Pancreatic Cancer

Feat. J. Gonzalez
27:37
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Expert Panel Discussion: Practice-Changing Updates

Feat. N. Uboha, A. Turk, K. Spencer, M. Cecchini
29:25
Young Chae

Hyperprogression in Cancer Treated With Immunotherapy

08:34
Yale Cancer Center

NORPACT-1 Trial Updates: Neoadjuvant FOLFIRINOX vs. Upfront Surgery …

Feat. J. Lacy
23:58
ASCO GI 2023 Conference Coverage

ASCO GI 2023 Key Studies

Feat. R. Kim, R. Mehta
20:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Summary: "GI Expert Panel Discussion on Key Trials I…

Feat. Y. Janjigian, S. Cytryn, S. Maron
31:40
Horizon CME

Updates in Perioperative Therapy of Pancreatic Cancer

Feat. P. Philip
13:47
Aditya Shreenivas

Neoadjuvant IO in MSI-High GI Cancers: Special Focus on the DREAM GI…

Feat. S. Chakrabarti
17:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Advancing GI Cancer Treatment - The Clinic…

Feat. S. Cohen
07:42
Integrity CE

Debates in Neoadjuvant Therapy in Resectable Pancreatic Cancer: Why …

Feat. W. Burns
06:03
Total Health

2024 Updates on Targeted Approaches for GI Cancers and New Data in N…

Feat. A. Grothey
19:41
Balazs Halmos

How I Manage Immune Adverse Events in Solid Tumors

17:02
Harshabad Singh

Targeting KRAS in Pancreatic Cancer

03:50
UCLA Health

Perspectives on the Recent FDA Approval of NALIRIFOX in Frontline Me…

Feat. Z. Wainberg
04:25
ecancer

ASCO® 2024 Insights: "Summary of the PASS-01 Trial - 1L FOLFIRI…

Feat. J. Knox